person · Reporting owner
Stevens Christopher James
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Chief Operating Officer | August 11, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date August 11, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 505,784 |
Reported balance
After 2026-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 36,658 · Balance 505,784 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 13, 2026 20:15 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 36,658 | $3.50 | $128,266.34 |
DisclosureSEC source: 0001140361-26-032818 · form4.xml · nonDerivative · entry 1 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,784 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 00:49 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 101,428 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001140361-26-031473 · form4.xml · derivative · entry 2 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,428 Underlying: Common Stock · 101,428 shares Expires 2036-08-03 F3 · derivative.exercise_date: This option represents a right to purchase a total of 101,428 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on August 3, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 00:49 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 73,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-031473 · form4.xml · nonDerivative · entry 1 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,442 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on August 3, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 93,037 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001140361-26-005408 · form4.xml · derivative · entry 2 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,037 Underlying: Common Stock · 93,037 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 61,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-005408 · form4.xml · nonDerivative · entry 1 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,129 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:11 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 554,071 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001140361-25-029144 · form4.xml · derivative · entry 2 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,071 Underlying: Common Stock · 554,071 shares Expires 2035-08-04 F2 · derivative.exercise_date: This option represents a right to purchase a total of 554,071 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:11 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 407,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-029144 · form4.xml · nonDerivative · entry 1 Stevens Christopher James · CIK 0002079768 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,166 F1 · security: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · shares: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.